Pushing Boundaries In Cancer Diagnosis

Dr Ravi Gaur, COO, Oncquest Laboratories in a candid conversation with Prathiba Raju talks about how Oncquest lab's advanced diagnosis has brought in precision, affordability in cancer diagnosis in India.

- 

How is molecular hematology and surgical pathology services is evolving in India. Oncquest Laboratories has a special focus on molecular oncology, can you tell us how have you evolved and progressed in the field?

Established in 2000, Oncquest Laboratoriesis known for its excellence in molecular diagnosis and its core competence in cancer diagnosis. Its key business areas include molecular diagnosis (oncology and infections ), advanced diagnosis, general pathology and microbiology, hospital lab management, clinical trails, and R&D. With over eighteen years of experience under its belt, Oncquest has established itself among India’s largest cancer diagnostic networks. It is a College of American Pathologists (CAP) and National Accreditation Board for Testing & Calibration Laboratories (NABL) accredited centre, with a core focus in Molecular Pathology and Surgical Pathology Services. The logistic capabilities and Pan-Asia geographical spread, makes Oncquest an ideal associate for all clinical activities in India and neighboring countries.

Oncquest utilises the experience and expertise of trained scientists and pathologist to provide clinicians an incisive diagnosis to identify the disease process at the fine point of differentiation. Recently, it has extended its arms in the areas of Companion Diagnostics and Pharmacogenomics which has encouraged greater penetration of personalised medicine into the Indian healthcare market. This is a way towards the future epicentre of the much technological advancement in healthcare.

What are the latest trends within the diagnostic market in India, particularly in cancer diagnostics?